Chronic non-invasive ventilation for chronic obstructive pulmonary disease.
Tim Raveling,Judith Vonk,Fransien M Struik,Roger Goldstein,Huib Am Kerstjens,Peter J Wijkstra,Marieke L Duiverman,Huib AM Kerstjens
DOI: https://doi.org/10.1002/14651858.CD002878.pub3
IF: 8.4
2021-08-11
Cochrane Database of Systematic Reviews
Abstract:Chronic non‐invasive ventilation (NIV) is increasingly being used to treat people with COPD who have respiratory failure, but the evidence supporting this treatment has been conflicting. To assess the effects of chronic non‐invasive ventilation at home via a facial mask in people with COPD, using a pooled analysis of IPD and meta‐analysis. We searched the Cochrane Airways Register of Trials, MEDLINE, Embase, PsycINFO, CINAHL, AMED, proceedings of respiratory conferences, clinical trial registries and bibliographies of relevant studies. We conducted the latest search on 21 December 2020. We included randomised controlled trials (RCTs) comparing chronic NIV for at least five hours per night for three consecutive weeks or more (in addition to standard care) versus standard care alone, in people with COPD. Studies investigating people initiated on NIV in a stable phase and studies investigating NIV commenced after a severe COPD exacerbation were eligible, but we reported and analysed them separately. The primary outcomes were arterial blood gases, health‐related quality of life (HRQL), exercise capacity (stable COPD) and admission‐free survival (post‐exacerbation COPD). Secondary outcomes for both populations were: lung function, COPD exacerbations and admissions, and all‐cause mortality. For stable COPD, we also reported respiratory muscle strength, dyspnoea and sleep efficiency. We used standard methodological procedures expected by Cochrane. After inclusion of a study, we requested the IPD. We analysed continuous and time‐to‐event data using linear‐ and cox‐regression mixed‐effect models with a random effect on study level. We analysed dichotomous IPD using generalised estimating equations. We adjusted all models for age and sex. We assessed changes in outcomes after three and 12 months. We also conducted a meta‐analysis on aggregated trial data. We included 14 new RCTs in this review update, in addition to the seven previously included. Seventeen studies investigated chronic NIV in stable COPD and four studies investigated chronic NIV commenced after a severe COPD exacerbation. Three studies compared NIV to sham continuous positive airway pressure (2 to 4 cmH 2 O). Seven studies used a nasal mask, one study used an oronasal mask and eight studies used both interfaces. Five studies did not report the interface. The majority of trials (20/21) were at high risk of performance bias due to an unblinded design. We considered 11 studies to have a low risk of selection bias and 13 to have a low risk of attrition bias. We collected and analysed the IPD from 13 stable COPD studies (n = 778, 68% of the participants included) and from three post‐exacerbation studies (n = 364, 96% of the participants included). In the stable COPD group, NIV probably results in a minor benefit on the arterial partial pressure of oxygen (PaO 2 ) after three months (adjusted mean difference (AMD) 0.27 kPa, 95% CI 0.04 to 0.49; 9 studies, 271 participants; moderate‐certainty evidence), but there was little to no benefit at 12 months (AMD 0.09 kPa, 95% CI ‐0.23 to 0.42; 3 studies, 171 participants; low‐certainty evidence). The arterial partial pressure of carbon dioxide (PaCO 2 ) was reduced in participants allocated to NIV after three months (AMD ‐0.61 kPa, 95% CI ‐0.77 to ‐0.45; 11 studies, 475 participants; high‐certainty evidence) and persisted up to 12 months (AMD ‐0.42 kPa, 95% CI ‐0.68 to ‐0.16; 4 studies, 232 participants; high‐certainty evidence). Exercise capacity was measured with the 6‐minute walking distance (minimal clinical important difference: 26 m). There was no clinically relevant effect of NIV on exercise capacity ( 3 months: AMD 15.5 m, 95% CI ‐0.8 to 31.7; 8 studies, 330 participants; low‐certainty evidence; 12 months: AMD 26.4 m, 95% CI ‐7.6 to 60.5; 3 studies, 134 participants; very low‐certainty evidence). HRQL was measured with the Severe Respiratory Insufficiency and the St. Georges's Respiratory Questionnaire and may be improved by NIV, but only after three months ( 3 months: standardised mean difference (SMD) 0.39, 95% CI 0.15 to 0.62; 5 studies, 259 participants; very low‐certainty evidence; 12 months: SMD 0.15, 95% CI ‐0.13 to 0.43; 4 studies, 200 participants; very low‐certainty evidence). Lastly, the risk for all‐cause mortality is likely reduced by NIV (adjusted hazard ratio (AHR) 0.75, 95% CI 0.58 to 0.97; 3 studies, 405 participants; moderate‐certainty evidence). In the post‐exacerbation COPD group, there was little to no benefit on the PaO 2 after three months, but there may be a slight decrease after 12 months ( 3 months: AMD ‐0.10 kPa, 95% CI ‐0.65 to 0.45; 3 studies, 234 participants; low‐certainty evidence; 12 months: ‐0.27 kPa, 95% CI ‐0.86 to 0.32, 3 studies; 170 participants; low‐certainty evidence). The PaCO 2 was reduced by NIV at both three months (AMD -Abstract Truncated-
medicine, general & internal